AI Brings Hope for Patients with Lyosomal Storage Disease

Artificial intelligence (AI) is becoming increasingly important in drug discovery. Advances in the use of Big Data, learning algorithms and powerful computers have now enabled researchers at the University of Zurich (UZH) to better understand a serious metabolic disease.

Cystinosis is a rare lyosomal storage disorder affecting around 1 in 100,000 to 200,000 newborns worldwide. Nephropathic (non-inflammatory) cystinosis, the most common and severe form of the disease, manifests with kidney disease symptoms during the first months of life, often leading to kidney failure before the age of 10. "Children with cystinosis suffer from a devastating, multisystemic disease, and there are currently no available curative treatments," says Olivier Devuyst, head of the Mechanisms of Inherited Kidney Disorders (MIKADO) group and co-director of the ITINERARE University Research Priority Program at UZH.

The UZH researchers worked with Insilico Medicine, a company that uses AI for drug discovery, to uncover the underlying cellular mechanism behind kidney disease in cystinosis. Leveraging model systems and Insilico’s PandaOmics platform, they identified the disease-causing pathways and prioritized therapeutic targets within cystinosis cells. Their findings revealed a causal association between the regulation of a protein called mTORC1 and the disease. Alessandro Luciani, one of the research group leaders, explains: “Our research showed that cystine storage stimulates the activation of the mTORC1 protein, leading to the impairment of kidney tubular cell differentiation and function.”

Promising drug identified for treatment

As patients with cystinosis often require a kidney transplant to restore kidney function, there is an urgent need for more effective treatments. Utilizing the PandaOmics platform, the UZH research team therefore embarked on a search for existing drugs that could be repurposed for cystinosis. This involved an analysis of the drugs’ structure, target enzymes, potential side effects and efficacy in the affected tissues. The already-licensed drug rapamycin was identified as a promising candidate for treating cystinosis. Studies in cell systems and model organisms confirmed that treatment with rapamycin restored the activity of lysosomes and rescued the cellular functions.

Olivier Devuyst and Alessandro Luciani are optimistic about future developments: "Although the therapeutic benefits of this approach will require further clinical investigations, we believe that these results, obtained through unique interdisciplinary collaboration, bring us closer to a feasible therapy for cystinosis patients."

Scientists from the University of Zurich (UZH), the Faculty of Medicine at UCLouvain in Brussels, the Microsoft Research-University of Trento Centre for Computational and Systems Biology, and the company Insilico Medicine were involved in the study. The USA's Cystinosis Research Foundation and the Swiss National Science Foundation (SNSF) provided funding for the study.

Berquez M, Chen Z, Festa BP, Krohn P, Keller SA, Parolo S, Korzinkin M, Gaponova A, Laczko E, Domenici E, Devuyst O, Luciani A.
Lysosomal cystine export regulates mTORC1 signaling to guide kidney epithelial cell fate specialization.
Nat Commun. 2023 Jul 14;14(1):3994. doi: 10.1038/s41467-023-39261-3

Most Popular Now

AI Tool Helps Predict Relapse of Pediatr…

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers. AI-assisted interpretation of brain scans may help improve...

Detecting Lung Cancer 4 Months Earlier a…

GPs may soon be able to identify patients with an increased risk of lung cancer up to 4 months earlier than is currently the case. The GP should be able...

Infectious Disease Surveillance Platform…

The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate...

Children's Health Ireland to Transf…

Healthcare teams responsible for paediatric care in Ireland are to save significant time in accessing important diagnostic imaging and reports, with the help of a new agreement with medical imaging...

NHS, Councils, and Housing could Share N…

A new technology partnership formally announced, could help NHS, local government, and housing organisations collaborate to create an unprecedented understanding of the risks and needs of people in their care...

AI-Powered Analysis of Stent Healing

Each year, more than three million people worldwide are treated with stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after implantation remains a...

Right Patient, Right Dose, Right Time

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin...

An AI Tool Grounded in Evidence-Based Me…

A powerful clinical artificial intelligence tool developed by University at Buffalo biomedical informatics researchers has demonstrated remarkable accuracy on all three parts of the United States Medical Licensing Exam (Step...

AXREM and BHTA Name Highland as 'Fu…

Hosted by trade associations AXREM and the British Healthcare Trades Association (BHTA), 'The Future of MedTech - Innovating for Tomorrow', will allow delegates to engage with speakers from the government...